Healthy Skepticism Library item: 12676

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Journal Article

Arnold RJ.
Cost-effectiveness analysis: should it be required for drug registration and beyond?
Drug Discov Today 2007 Nov; 12:(21-22):960-5
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T64-4R17336-5&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=9647b88a81c87de2fdd05ad128ba0f45

Abstract:

Cost-effectiveness analysis (CEA) is applied in situations where trade-offs exist, typically, greater benefit for an increased cost over an alternative therapy or strategic option versus usual care. CEA is useful where a new strategy is more costly but expected to be more effective or where a new strategy is less costly but less effective. A good example for the relevance of CEA is the unanimous recommendation of a US federal vaccine advisory panel to vaccinate 11-year-old girls against cervical cancer. This recommendation was at least partly because of data showing the relative cost-effectiveness of HPV vaccine. In this era of finite budgets, CEA may facilitate drug development, drug approval, patient segmentation and pricing model development throughout the drug lifecycle continuum.

Keywords:
Cost-Benefit Analysis* Decision Making Drug Approval* Drug Industry Female Humans Papillomavirus Vaccines/economics Papillomavirus Vaccines/immunology Registries* Uterine Cervical Neoplasms/prevention & control